Transrectal ultrasound for intraoperative interstitial needle guidance in cervical cancer brachytherapy.

Cervical neoplasms Female urogenital diseases Image-guided adaptive brachytherapy Image-guided radiotherapy TRUS

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
26 Feb 2024
Historique:
received: 15 11 2023
accepted: 23 01 2024
medline: 27 2 2024
pubmed: 27 2 2024
entrez: 27 2 2024
Statut: aheadofprint

Résumé

This study aimed to prospectively assess the visibility of interstitial needles on transrectal ultrasound (TRUS) in cervical cancer brachytherapy patients and evaluate its impact on implant and treatment plan quality. TRUS was utilized during and after applicator insertion, with each needle's visibility documented through axial images at the high-risk clinical target volume's largest diameter. Needle visibility on TRUS was scored from 0 (no visibility) to 3 (excellent discrimination, margins distinct). Quantitative assessment involved measuring the distance between tandem and each needle on TRUS and comparing it to respective magnetic resonance imaging (MRI) measurements. Expected treatment plan quality based on TRUS images was rated from 1 (meeting all planning objectives) to 4 (violation of High-risk clinical target volume (CTV Analysis included 23 patients with local FIGO stage IB2-IVA, comprising 41 applications with a total of 230 needles. A high visibility rate of 99.1% (228/230 needles) was observed, with a mean visibility score of 2.5 ± 0.7 for visible needles. The maximum and mean difference between MRI and TRUS measurements were 8 mm and -0.1 ± 1.6 mm, respectively, with > 3 mm discrepancies in 3.5% of needles. Expected treatment plan quality after TRUS assessment exactly aligned with the final MRI plan in 28 out of 41 applications with only minor deviations in all other cases. Real-time TRUS-guided interstitial needle placement yielded high-quality implants, thanks to excellent needle visibility during insertion. This supports the potential of TRUS-guided brachytherapy as a promising modality for gynecological indications.

Identifiants

pubmed: 38409394
doi: 10.1007/s00066-024-02207-9
pii: 10.1007/s00066-024-02207-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Austrian Science Fund
ID : KLI695-B33

Informations de copyright

© 2024. The Author(s).

Références

Cibula D et al (2023) ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer—Update 2023. Int J Gynecol Cancer 1;33(5):649–666 (May)
doi: 10.1136/ijgc-2023-004429
Fokdal L et al (2013) Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component. Radiother Oncol 107(1):63–68 (Apr)
doi: 10.1016/j.radonc.2013.01.010 pubmed: 23452917
Van Dyk S et al (2009) Conformal brachytherapy planning for cervical cancer using transabdominal ultrasound. Int J Radiat Oncol Biol Phys 1;75(1):64–70 (Sep)
pubmed: 19250767
Epstein E et al (2013) Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound—A European multicenter trial. Gynecol Oncol 128(3):449–453 (Mar)
doi: 10.1016/j.ygyno.2012.09.025 pubmed: 23022593
Schmid MP et al (2013) Feasibility of transrectal ultrasonography for assessment of cervical cancer. Strahlenther Onkol 189(2):123–128 (Feb)
doi: 10.1007/s00066-012-0258-1 pubmed: 23255091
Schmid MP et al (2016) Transrectal ultrasound for image-guided adaptive brachytherapy in cervix cancer—An alternative to MRI for target definition? Radiother Oncol 120(3):467–472 (Sep)
doi: 10.1016/j.radonc.2016.01.021 pubmed: 26921168
Smet S et al (2020) Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer. Strahlenther Onkol 196(11):983–992 (Nov)
doi: 10.1007/s00066-020-01656-2 pubmed: 32621011 pmcid: 7653783
Dimopoulos JC et al (2012) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 103(1):113–122 (Apr)
doi: 10.1016/j.radonc.2011.12.024 pubmed: 22296748 pmcid: 3336085
Pötter R., et al.; The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018 Jan 11;9:48–60.
Knoth J., et al.; Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer. Brachytherapy. 2022 Mar-Apr;21(2):186–192.
Rodgers JR et al (2019) Intraoperative 360-deg three-dimensional transvaginal ultrasound during needle insertions for high-dose-rate transperineal interstitial gynecologic brachytherapy of vaginal tumors. J Med Imaging (bellingham) 6(2):25001 (Apr)
pubmed: 30989088
Siebert FA et al (2020) GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy. Radiother Oncol 148:51–56 (Jul)
doi: 10.1016/j.radonc.2020.02.024 pubmed: 32335363
Batchelar D., et al.; Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning. Brachytherapy. 2014 Jan-Feb;13(1):75–9.
Zheng D., et al.; A novel method for accurate needle-tip identification in trans-rectal ultrasound-based high-dose-rate prostate brachytherapy. Brachytherapy. 2011 Nov-Dec;10(6):466–73.
Siebert FA et al (2009) Imaging of implant needles for real-time HDR-brachytherapy prostate treatment using biplane ultrasound transducers. Med Phys 36(8):3406–3412 (Aug)
doi: 10.1118/1.3157107 pubmed: 19746773
Nesvacil N., et al.; Combining transrectal ultrasound and CT for image-guided adaptive brachytherapy of cervical cancer: Proof of concept. Brachytherapy. 2016 Nov–Dec;15(6):839–844.
Poulin E et al (2015) Fast, automatic, and accurate catheter reconstruction in HDR brachytherapy using an electromagnetic 3D tracking system. Med Phys 42(3):1227–1232 (Mar)
doi: 10.1118/1.4908011 pubmed: 25735278
Yang Z et al (2020) Verification of needle guidance accuracy in pelvic phantom using registered ultrasound and MRI images for intracavitary/interstitial gynecologic brachytherapy. J Contemp Brachytherapy 12(2):147–159 (Apr)
doi: 10.5114/jcb.2020.94583 pubmed: 32395139 pmcid: 7207233
Dehghan E et al (2018) EM-enhanced US-based seed detection for prostate brachytherapy. Med Phys 45(6):2357–2368 (Jun)
doi: 10.1002/mp.12894 pubmed: 29604086
Bharat S et al (2014) Electromagnetic tracking for catheter reconstruction in ultrasound-guided high-dose-rate brachytherapy of the prostate. Brachytherapy Nov-dec 13(6):640–650
doi: 10.1016/j.brachy.2014.05.012
Boutaleb S et al (2015) Performance and suitability assessment of a real-time 3D electromagnetic needle tracking system for interstitial brachytherapy. J Contemp Brachytherapy 7(4):280–289 (Aug)
doi: 10.5114/jcb.2015.54062 pubmed: 26622231 pmcid: 4643737
Beaulieu L et al (2018) Real-time electromagnetic tracking based treatment platform for high-dose-rate prostate brachytherapy: Clinical workflows and end-to-end validation. Brachytherapy. Jan 17(1):103–110

Auteurs

J Knoth (J)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

A Sturdza (A)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

A Zaharie (A)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

V Dick (V)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

G Kronreif (G)

Austrian Center for Medical Innovation and Technology, Wiener Neustadt, Austria.

N Nesvacil (N)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

J Widder (J)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

C Kirisits (C)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

M P Schmid (MP)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. maximilian.a.schmid@meduniwien.ac.at.

Classifications MeSH